Folio · SPXSet Report · Digest
v0.7.0 STABLE · 2026-11-11 · r4

2026-W46 · Nov 9–Nov 15 · Company · Profile · published

Index >>> Company >>> Profile

GE HealthCare Technologies Inc. (GEHC) — XLV Health Care · S&P 500 Profile |GE 醫療公司介紹

health-careS&P500xlv
SPXSet Studio
IN-HOUSE RESEARCH · 站內獨立研究

GE HealthCare Technologies Inc. (GEHC) — Business, History & S&P 500 Profile | GE 醫療公司介紹

GE HealthCare Technologies Inc. company profile · business segments · history · financial snapshot · S&P 500 rank #290 · GE 醫療公司業務歷史財務與標普500地位

中文版 ↓

PROFILE
Market data as of Nov 3, 2026
Financials: FY2025
MARKET CAP
$36.10B
Nov 3, 2026 close
S&P 500 WEIGHT
0.05%
Rank #290 · Nov 3, 2026
SECTOR RANK
#37
Health Care · Nov 3, 2026
S&P 500 RANK
#290
0.05% · Nov 3, 2026

SNAPSHOT

TickerGEHC
CompanyGE HealthCare Technologies Inc.
GICS sector / industryHealth Care (XLV) / Health Care Equipment
S&P 500 rank (by weight)#290 · 0.05% (Nov 3, 2026)
Sector rank#37 in Health Care (Nov 3, 2026)
HeadquartersChicago, Illinois, United States
Founded1994
CEOPeter Arduini (President and CEO)
Employees~54,000 (2025)
Market cap$36.10B (Nov 3, 2026)
Share price$79.41 (Nov 3, 2026)
SEC filingsEDGAR — CIK 0001932393

WHAT IT DOES

GE HealthCare Technologies is a global medical-technology and diagnostics company headquartered in Chicago, spun off from General Electric in January 2023. It supplies the imaging scanners, ultrasound systems, patient-monitoring equipment and pharmaceutical diagnostics that hospitals and clinics use to see inside the body and guide treatment.

The model is installed-base economics: a very large fleet of scanners and monitors in hospitals worldwide generates recurring service contracts, parts and software revenue alongside new equipment sales, and its Pharmaceutical Diagnostics unit sells the contrast agents consumed by those scans.

In fiscal 2025 GE HealthCare reported revenues of $20,625M, up 4.84% year over year, operating income of $2,763M and net income of $2,084M (diluted EPS $4.55), its third year as an independent company.

BUSINESS SEGMENTS

ImagingCT, MR, molecular imaging, X-ray, mammography and surgical imaging systems: $9,245M of fiscal 2025 revenues — the largest segment, about 45% of the total (fiscal 2025 Form 10-K).
Advanced Visualization SolutionsUltrasound and image-guided therapy systems, including cardiovascular, women's health and point-of-care ultrasound: $5,354M of fiscal 2025 revenues.
Patient Care SolutionsPatient monitoring, anesthesia delivery, diagnostic cardiology and maternal-infant care equipment: $3,086M of fiscal 2025 revenues.
Pharmaceutical DiagnosticsContrast media and molecular imaging agents used with imaging procedures: $2,900M of fiscal 2025 revenues — the group's consumables stream.
OtherPrincipally Healthcare Financial Services (equipment financing): about $40M of fiscal 2025 revenues (residual of reported segment revenues versus the group total).

HISTORY

YearMilestone
1994GE's medical systems business organized as the healthcare subsidiary that became GE Healthcare (roots run to early X-ray pioneers).
2004GE completed the acquisition of Amersham plc (about $9.5B), adding life sciences and the diagnostics/media business that anchors Pharmaceutical Diagnostics.
2022GE HealthCare Technologies Inc. formed as the spin-off vehicle (May 16, 2022) as GE prepared its three-way breakup.
2023Spin-off from GE completed (January 2023); GE HealthCare began trading on Nasdaq and joined the S&P 500.
2025Third year as an independent company: revenues rose 4.84% to $20,625M with net income of $2,084M.

COMPETITIVE POSITION

  • One of the "big three" global imaging suppliers alongside Siemens Healthineers and Philips, with Canon Medical and Fujifilm in specific modalities.
  • A vast installed base of scanners and monitors underpins recurring service and parts revenue and switching costs for hospitals.
  • Pharmaceutical Diagnostics adds a consumables stream — contrast agents are used with every scan — that equipment-only rivals lack at this scale.
  • Competes on AI-assisted imaging, workflow software and total cost of ownership as hospital capital budgets stay tight.

FINANCIAL SNAPSHOT

Total revenue$20.63B — FY2025 total revenues, +4.84% year over year
Operating income$2,763M — FY2025 operating income (EBIT)
Net income attributable to GE HealthCare$2,084M — FY2025 net income attributable to GE HealthCare
Diluted EPS$4.55 — FY2025 diluted EPS
Source: GE HealthCare fiscal 2025 results (year ended Dec 31, 2025) — StockAnalysis financials, compiled from the fiscal 2025 Form 10-K, including segment revenues. Corroborated by the Wikipedia company profile (retrieved Nov 3, 2026).

KEY RISKS

  • Hospital capital budgets: equipment demand follows health-system finances and procedure volumes, and softened in several markets in recent years.
  • China exposure: demand, local competition and volume-based procurement pricing in China have been a recurring headwind for imaging vendors.
  • Tariffs and supply chains: global manufacturing and specialized inputs (including contrast-media ingredients) expose margins to trade policy and shortages.
  • Technology transition: AI-native imaging entrants and software-first rivals could compress hardware pricing over time.
  • Legacy of the GE separation: shared liabilities and the smaller scale of a standalone balance sheet versus its former parent.

WHY IT MATTERS FOR THE S&P 500

GE HealthCare is #290 in the S&P 500 with a 0.05% weight (Nov 3, 2026) and #37 of 60 in Health Care by market cap; at $36.10B it is the index's principal pure-play medical-imaging equipment name — a 2023 spin-off carrying a century-scale installed base, and one of the clearest index proxies for global hospital capital spending.

SOURCES & METHODOLOGY

Financials, segments, headquartersGE HealthCare fiscal 2025 Form 10-K compilation via StockAnalysis; company site and Wikipedia for identity (retrieved Nov 3, 2026)
Index weight & ranksSlickcharts S&P 500 weights and market caps, fetched Nov 3, 2026 (fresh snapshot for this batch)
Market cap$36.10B (Nov 3, 2026)
LogoSPXSet logo library, compiled from company official websites, filings, or Wikipedia; as company logos are dynamic corporate information, no 100% guarantee is made for the graphics.
ChartSPXSet chart library, monthly bars, compiled from Yahoo public information.

Price Chart — 10-Year Monthly Candles

GEHC

Source: Yahoo Finance monthly bars, split-adjusted · Data as of Sep 30, 2026 (last closed month) · SPXSet.com

FINANCIALS

繁體中文版

公司快照

股票代號GEHC
公司GE HealthCare Technologies Inc.(GE 醫療)
GICS 板塊/行業醫療保健(XLV)/醫療保健設備
標普500排名(按權重)#290 · 0.05%(Nov 3, 2026)
板塊內排名醫療保健 #37(Nov 3, 2026)
總部美國伊利諾伊州芝加哥
成立1994年
執行長Peter Arduini(總裁兼執行長)
員工約54,000(2025年)
市值$36.10B(Nov 3, 2026)
股價$79.41(Nov 3, 2026)
SEC 申報EDGAR — CIK 0001932393

業務概覽

GE HealthCare Technologies 是總部位於芝加哥的全球醫療科技與診斷公司,2023 年 1 月自通用電氣分拆獨立。它供應醫院與診所用以透視人體、引導治療的影像掃描儀、超聲波系統、病人監護設備及藥物診斷產品。

其模式是裝機量經濟:遍佈全球醫院的大量掃描儀與監護設備,在新設備銷售之外帶來經常性的服務合約、零件與軟件收入;藥物診斷部門則銷售掃描所消耗的造影劑。

2025 財年 GE HealthCare 收入 206.25 億美元、按年增長 4.84%,營業利潤 27.63 億美元、淨利潤 20.84 億美元(稀釋每股盈利 4.55 美元),為獨立營運第三年。

業務板塊

影像CT、MR、分子影像、X 光、乳房造影及手術影像系統:2025 財年收入 92.45 億美元,是最大板塊,約佔總額 45%(2025 財年 Form 10-K)。
先進可視化解決方案超聲波及影像引導治療系統,包括心血管、婦女健康與床邊超聲波:2025 財年收入 53.54 億美元。
病人護理解決方案病人監護、麻醉輸送、診斷心臟學及母嬰護理設備:2025 財年收入 30.86 億美元。
藥物診斷影像檢查所用的造影劑及分子影像藥劑:2025 財年收入 29.00 億美元,是集團的耗材收入來源。
其他主要為醫療金融服務(設備融資):2025 財年收入約 0.40 億美元(已列報板塊收入與集團總額的差額)。

歷史沿革

年份里程碑
1994GE 的醫療系統業務組建為後來的 GE Healthcare 子公司(源流可溯至早期 X 光先驅)。
2004GE 完成收購 Amersham plc(約 95 億美元),加入生命科學及診斷/造影劑業務,成為今日藥物診斷板塊的根基。
2022GE HealthCare Technologies Inc. 成立為分拆載體(2022 年 5 月 16 日),配合 GE 的三分拆計劃。
2023自 GE 的分拆完成(2023 年 1 月);GE HealthCare 於 Nasdaq 掛牌並加入標普500。
2025獨立營運第三年:收入增長 4.84% 至 206.25 億美元,淨利潤 20.84 億美元。

競爭地位

  • 全球影像設備「三大」供應商之一,與 Siemens Healthineers 及 Philips 並列;Canon Medical 與 Fujifilm 在個別成像領域競爭。
  • 龐大的掃描儀與監護設備裝機量,支撐經常性服務與零件收入,並為醫院帶來轉換成本。
  • 藥物診斷帶來耗材收入——每次掃描均消耗造影劑——是純設備同行在此規模上所欠缺的。
  • 在醫院資本預算緊絀下,以 AI 輔助影像、工作流程軟件與整體擁有成本競爭。

財務快照

總收入206.3 億美元 — 2025 財年總收入,按年增長 4.84%
營業利潤27.63 億美元 — 2025 財年營業利潤(EBIT)
歸屬於 GE HealthCare 的淨利潤20.84 億美元 — 2025 財年歸屬於 GE HealthCare 的淨利潤
稀釋每股盈利4.55 美元 — 2025 財年稀釋每股盈利
來源:GE HealthCare 2025 財年業績(年度截至 2025 年 12 月 31 日)— StockAnalysis 財務數據,整理自 2025 財年 Form 10-K,包括板塊收入。並以維基百科公司條目核對(2026 年 11 月 3 日讀取)。

主要風險

  • 醫院資本預算:設備需求跟隨醫療系統財務與檢查量,近年在多個市場放緩。
  • 中國敞口:需求、本土競爭與帶量採購定價,一直是影像設備商的逆風。
  • 關稅與供應鏈:全球生產佈局與專用投入(包括造影劑成分)令利潤率受貿易政策與短缺影響。
  • 技術轉型:AI 原生影像新進者與軟件先行的對手,長遠或壓縮硬件定價。
  • GE 分拆遺留:與前母公司分擔的責任,以及獨立後較小的資產負債表規模。

對標普500的重要性

GE HealthCare 在標普500排名 #290、權重 0.05%(2026 年 11 月 3 日),在醫療保健板塊以市值計排第 37(共 60 家);市值 361.0 億美元,是指數內主要的純醫療影像設備股——一間 2023 年分拆、承載逾百年裝機基礎的公司,也是環球醫院資本開支最清晰的指數指標之一。

來源與方法

財務、板塊、總部GE HealthCare 2025 財年 Form 10-K 整理(經 StockAnalysis);公司官網及維基百科核對公司身份(2026 年 11 月 3 日讀取)
指數權重與排名Slickcharts 標普500權重與市值,2026 年 11 月 3 日抓取(本批新鮮快照)
市值$36.10B(Nov 3, 2026)
LogoSPXSet logo 庫,整理自企業官方網站、文件或維基百科;由於是企業自身動態資訊,不對圖形做百分百保證。
股價圖SPXSet 圖表庫月線,整理自 Yahoo 公開資訊。

10年股價K線圖(月K)

GEHC

來源:Yahoo Finance 月線(經拆股調整)· 數據截至 2026 年 9 月 30 日(最後已收月份)· SPXSet.com

月線共 45 根,2023 年 1 月至 2026 年 9 月(2023 年 1 月自 GE 分拆後於 Nasdaq 上市)。首根(2023 年 1 月)收市 $69.52;2026 年 9 月:開市 $71.25、高 $71.88、低 $62.99、收市 $65.37。期內高位 $94.80(2025 年 2 月);期內低位 $53.50(2023 年 1 月)。

財報

SPXSet Studio

SPXSet in-house research — market structure, options and volatility. Not investment advice.
SPXSet 站內獨立研究,聚焦 SPX 市場結構、期權與波動率;內容不構成投資建議。

SPXSet · Company Library · GEHC
Data as of Nov 3, 2026 · Financials FY2025 (10-K) · Market data Nov 2026
Previous · The Hartford Insurance Group, Inc. (HIG) — XLF Financials · S&P 500 Profile |哈特福德保險集團公司介紹Next · Illumina, Inc. (ILMN) — XLV Health Care · S&P 500 Profile |因美納公司介紹

Entered 2026-11-03 10:34 · updated 2026-11-14 23:26 · rev 8